Caris Initiates Coverage on Spectranetics (SPNC) with an Average
More News related to SPNC
- Milberg LLP Continues Its Investigation On Behalf of Certain Investors of Spectranetics Corporation
- Brower Piven Announces Expanded Class Period and Encourages Investors Who Have Losses in Excess of $100,000 From Investment in The Spectranetics Corporation to Inquire About the Lead Plaintiff Positio
- Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Files Class Action Lawsuit Against The Spectranetics Corp.
- Spectranetics Receives NASDAQ Notice
- Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Caris initiates coverage on Spectranetics (Nasdaq: SPNC) with an Average. Price target $5.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system for use with Spectranetics' excimer laser system.
Related Categories
New CoverageStocks Mentioned
+0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
